Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Sanofi (OtherSNYNF)
Analysts fell to the sidelines weighing in on Pfizer (PFE) and Sanofi (SNYNF) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pfizer (PFE)
J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer today and set a price target of $30.00. The company’s shares closed last Thursday at $27.22.
According to TipRanks.com, Schott is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $28.97 average price target, which is a 6.5% upside from current levels. In a report issued on March 30, Bernstein also maintained a Hold rating on the stock with a $30.00 price target.
See the top stocks recommended by analysts >>
Sanofi (SNYNF)
UBS analyst Matthew Weston maintained a Hold rating on Sanofi today and set a price target of EUR88.00. The company’s shares closed last Thursday at $93.85, close to its 52-week low of $88.90.
According to TipRanks.com, Weston is ranked #1710 out of 12128 analysts.
Currently, the analyst consensus on Sanofi is a Moderate Buy with an average price target of $109.38, which is a 16.5% upside from current levels. In a report issued on March 30, J.P. Morgan also maintained a Hold rating on the stock with a EUR95.00 price target.
Read More on PFE:
Disclaimer & DisclosureReport an Issue
- Pfizer price target lowered to $26 from $27 at BofA
- Option traders moderately bearish in Pfizer with shares down 2.5%
- Pfizer’s New Phase 1 PF-07328948 Study Signals Ongoing Pipeline Investment
- Pfizer Targets Advanced Kidney Cancer With New PF-08634404 Trial: What Investors Should Know
- Mixed options sentiment in Pfizer with shares down 1.57%
